OmniPathology at ADLM 2026: Advancing the Future of Laboratory Medicine
Pictured: Mohammad Kamal, MD, CEO of OmniPathology, and Ronald Blum, Ph.D., Vice President of Science & Technology, at ADLM 2026 in Anaheim, California.
OmniPathology recently joined laboratory medicine leaders from around the world at ADLM 2026 in Anaheim, California, for several days of collaboration, innovation, and conversations about the future of diagnostics and pathology.
The conference brought together experts from across the laboratory medicine ecosystem, including diagnostics, artificial intelligence, digital pathology, automation, molecular diagnostics, contract research organizations (CROs), and clinical trials.
For OmniPathology, ADLM provided an opportunity to explore some of the technologies and advancements transforming healthcare today ~ from AI-driven laboratory workflows and digital pathology to molecular multiplexing, automation, novel diagnostic technologies, and continued advances in oncology, infectious disease, and autoimmune testing.
The conversations also extended beyond emerging technology to some of the most significant challenges facing laboratories and diagnostic organizations today, including evolving MolDx policies, reimbursement pressures, increasing regulatory requirements, and a changing healthcare policy landscape.
As laboratory medicine continues to evolve, collaboration among industry, clinical practice, research, and technology will be essential to ensuring that innovation ultimately translates into better patient care.
ADLM also continues to provide an important forum for developing new partnerships, advancing test validation initiatives, expanding clinical trial opportunities, and exchanging ideas that will help shape the future of precision diagnostics and pathology.
OmniPathology looks forward to continuing the conversations started in Anaheim and working with partners across the industry to advance laboratory medicine and improve patient outcomes.
